title: Disease duration did not influence the rates of loss of efficacy of the anti-TNF therapy in Latin American Crohn’s disease patients.
abstract: OBJECTIVE
  The efficacy of both Infliximab (IFX) and Adalimumab (ADA) can be reduced over time. The aim of this study was to analyze the incidence of loss of efficacy (LOE) of both IFX and ADA, and outline the influence of disease duration on its occurrence.
  
  
  METHODS
  Retrospective, multicenter, observational cohort study, with CD patients treated with anti-TNF therapy. LOE was defined as the need for steroids, occurrence of major abdominal surgery during treatment, dose increase, interval shortening or switching of the anti- TNF agent. Patients were allocated in three subgroups based on disease duration (DD): <24 months, between 24 and 60 months and >60 months.
  
  
  RESULTS
  175 patients were included in the study (117 under IFX and 58 under ADA therapy). LOE occurred in 32% of patients with DD <24 months, in 33.3% with DD between 24 and 60 months and in 31.3% of subjects with DD over 60 months (p = 0.975).
  
  
  CONCLUSIONS
  Disease duration (DD) did not influence LOE rates. These results suggest that in real-world observational practice, patients with early CD might have the same rates of LOE than patients with a disease prolonging for a longer duration.
authors.forename: Paulo Gustavo
authors.initials: PG
authors.lastname: Kotze
authors.forename: Juliano Coelho
authors.initials: JC
authors.lastname: Ludvig
authors.forename: Fábio Vieira
authors.initials: FV
authors.lastname: Teixeira
authors.forename: Everson Fernando
authors.initials: EF
authors.lastname: Malluta
authors.forename: Eron Fábio
authors.initials: EF
authors.lastname: Miranda
authors.forename: Marcelo Raisweiler
authors.initials: MR
authors.lastname: Hardt
authors.forename: Márcia
authors.initials: M
authors.lastname: Olandoski
authors.forename: Lorete Maria
authors.initials: LM
authors.lastname: da Silva Kotze
authors.forename: Harry
authors.initials: H
authors.lastname: Kleinubing
mesh_terms: D000068879:Adalimumab; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D001938:Brazil; D003424:Crohn Disease / Q000188:drug therapy* / Q000601:surgery; D013505:Digestive System Surgical Procedures / Q000706:statistics & numerical data; D018450:Disease Progression; D004305:Dose-Response Relationship, Drug; D004351:Drug Resistance; D005260:Female; D006801:Humans; D000069285:Infliximab; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D013256:Steroids / Q000627:therapeutic use; D013997:Time Factors; D016896:Treatment Outcome; D000079424:Tumor Necrosis Factor Inhibitors
chemical_list: D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D013256:Steroids; D000079424:Tumor Necrosis Factor Inhibitors; D000069285:Infliximab; D000068879:Adalimumab